Odonate announces 'positive' results but faces investor backlash; Aslan is once again recruiting clinical trial participants after months-long wait amid the pandemic
Odonate Therapeutics announced “positive top-line results” from a Phase III study of their lead cancer drug. And sure enough, tesetaxel improved progression-free survival for metastatic breast cancer patients over placebo by 2.9 months.
But investors also appeared to see something else: a 71% rate of neutropenia for patients in the treatment arm, vs. a 8.3% rate for the control group, who received the generic chemotherapy capecitabine. The Phase III study covered 685 patients.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters